Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI
Highlights: ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patients Patients who received ISM001-055 showed dose-dependent improvement in the efficacy endpoint,as measured